Merck Just Paid $400M for a Drug That Doesn't Exist Yet

In preclinical testing, the drug showed nanomolar antiproliferative activity (extremely potent cell-killing at tiny concentrations) across multiple KRAS G12D-mutant cell lines. It also shrank tumors in animal models and looked clean in a 28-day repeat-dose toxicology study in rodents.

Oh, and it's oral. That's a big deal. Many early KRAS G12D drug candidates struggled with the basic medicinal chemistry challenge of turning a potent lab compound into a pill that survives the digestive system and reaches tumors at useful levels. An oral drug with good pharmacokinetics is table stakes for a commercially viable cancer medicine; it's just really hard to pull off for this target.

A Very Crowded Starting Line

Merck isn't the only one chasing KRAS G12D. The race has turned into a full sprint, and SPR2015 is actually behind several competitors that are already in human trials.

Astellas has pushed its candidate, setidegrasib, into a Phase 3 study in lung cancer. That's one of the most advanced programs in the field right now. Revolution Medicines is running a Phase 3 trial for zoldonrasib in first-line metastatic pancreatic cancer. Verastem expanded into three Phase 2 registration-directed studies across pancreatic, lung, and colorectal cancers in 2026. Even Incyte has a Phase 3 trial running.

So why would Merck pay $400 million upfront for a drug that's still in the lab? Two reasons.

First, differentiated mechanism. The molecular glue approach and cyclophilin A recruitment could give SPR2015 a different efficacy or safety profile compared to the non-covalent inhibitors already in the clinic. In a crowded field, being different is an asset.

Second, combination potential. Merck already has calderasib (MK-1084), a KRAS G12C inhibitor with Breakthrough Therapy designation in combination with its blockbuster KEYTRUDA. A KRAS G12D drug would let Merck run the same playbook across the broader KRAS-mutant patient population. It's not just buying a drug; it's buying a platform.

China: Big Pharma's Favorite Shopping Mall

This deal is part of a pattern that's now impossible to ignore. U.S. drugmakers have been raiding Chinese biotech pipelines at an accelerating pace. Through just the first half of 2025, American pharma companies signed 14 deals worth $18.3 billion to license drugs from China-based companies. By some estimates, nearly half of all U.S. in-licensing transactions in 2025 were sourced from Chinese partners.

Pfizer paid $1.25 billion upfront for a PD-1/VEGF bispecific antibody from 3SBio, with total deal value reaching roughly $6 billion. Pfizer then followed up with Innovent Biologics on a deal covering 12 early-stage cancer medicines worth up to $10.5 billion. Bristol Myers Squibb and GSK have both done major deals with Hengrui.

The commercial logic is straightforward. Chinese biotechs are producing high-quality assets at valuations that look cheap compared to equivalent Western programs. They often already have preclinical or early clinical data, which means the U.S. buyer gets a head start without paying late-stage prices. It's like shopping at an outlet mall where the brands are just as good but the sticker price is lower.

The $1.73 Billion Question

Merck got global rights to develop, manufacture, and sell SPR2015 anywhere in the world. The deal is already closed. Beyond the $400 million upfront, SciBrunch could earn up to $1.73 billion in milestone payments if the drug hits its development and commercial targets.

That's a big "if" for a preclinical asset. Most drugs that look good in mice never make it through human trials. The history of cancer drug development is littered with spectacular preclinical results that crumbled on contact with actual patients.

But Merck clearly believes the KRAS G12D opportunity is large enough, and SPR2015's mechanism is differentiated enough, to justify the risk. With over 30 registrational studies already running in its oncology pipeline, Merck isn't betting the farm on one molecule. It's adding another card to what's already a strong hand.

The real test comes when SPR2015 enters first-in-human trials. That's when we'll find out whether this molecular glue sticks, or if $400 million just became the most expensive science experiment of 2026.

The MS Drug That Doesn't Kill Your Immune Cells (It Just Calms Them Down)

Novartis's remibrutinib just beat an older MS drug in two large Phase 3 trials, but the real story is *how* it works. Unlike treatments that destroy or trap immune cells, this BTK inhibitor simply tells them to stand down. And in a competitive race littered with safety failures, that distinction could be worth billions.